HR 5882
GENE Therapy Payment Act
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill allows state Medicaid programs to negotiate with drug manufacturers through risk-sharing agreements for certain gene therapy drugs. These agreements would be for outpatient drugs intended to provide a potential cure for serious or life-threatening rare diseases after a limited number of administrations. The bill requires the Secretary of Health and Human Services to approve these agreements, ensuring they don't increase federal spending and that manufacturers provide necessary information. It also establishes a framework for installment payments and includes provisions to address subsequent drug approvals and ensure program integrity.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Kurt Schrader
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.